News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

Sosei Licenses TransMID from KS Biodex


Posted on: 05/29/2002

Sosei Licenses TransMID from KS Biodex

KS Biomedix Holdings has appointed Sosei as the Japanese licensee for TransMID, a biopharmaceutical product being developed to treat recurrent high grade glioma. Japan has about 20% of the total worldwide market for glioma treatments.

TransMID is based on the transferrin-mediated delivery of a modified diphtheria toxin that can selectively kill malignant cells. A completed phase II US study showed promising clinical response rates and improved survival times in patients with recurrent brain cancer. The FDA granted the product fast-track status in August 2001 and orphan drug status for the treatment of malignant tumors of the central nervous system in December 2001; the European Medicines Evaluation Agency's Committee for Orphan Medicinal Products granted the product orphan designation to treat glioma in March 2002.

Under the terms of the deal, KS Biomedix will receive a total of up to $25 million from Sosei and royalties on product sales, along with revenue from the sale to Sosei of TransMID materials manufactured at KSB's Edmonton. Sosei will develop, register, and market TransMID in Japan. A phase III trial for TransMID107-RTM for recurrent high grade glioma will begin in North America and Europe in the second half of calendar 2002; marketing submission is scheduled for 2004.
Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740